New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
10:03 EDTGEVA, YELP, MNK, EL, ARMH, LG, PAL, FEYE, WBC, HUBG, LLY, ONNN, VIPS, WWWW, NKE, HAR, ALGT, CACIOn The Fly: Analyst Upgrade Summary
ARM Holdings (ARMH) upgraded to Market Perform from Underperform at Bernstein... Allegiant Travel (ALGT) upgraded to Buy from Hold at Deutsche Bank... Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital... Estee Lauder (EL) upgraded to Outperform from Market Perform at Bernstein... Harman (HAR) upgraded to Strong Buy from Outperform at Raymond James...Hub Group (HUBG) upgraded to Buy from Hold at BB&T... Mallinckrodt (MNK) upgraded to Outperform from Market Perform at BMO Capital... Nike (NKE) upgraded to Buy from Hold at Stifel... S Ecology (ECOL) upgraded to Buy from Hold at KeyBanc... WABCO (WBC) upgraded to Conviction Buy from Buy at Goldman... Yelp (YELP) upgraded to Buy from Neutral at SunTrust... Web.com (WWWW) upgraded to Buy from Hold at Craig-Hallum... FireEye (FEYE) upgraded at Wedbush... Synageva (GEVA) upgraded at Wedbush... Vipshop (VIPS) upgraded to Outperform from Neutral at Credit Suisse... North American Palladium (PAL) upgraded to Sector Performer at CIBC... CACI International (CACI) upgraded to Outperform from Underperform at Raymond James... ON Semiconductor (ONNN) upgraded to Buy from Neutral at MKM Partners... Laclede (LG) upgraded to Buy from Hold at Stifel.
News For ARMH;ALGT;LLY;EL;HAR;HUBG;MNK;NKE;WBC;YELP;WWWW;FEYE;GEVA;VIPS;PAL;CACI;ONNN;LG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
June 22, 2015
06:07 EDTVIPSVipshop recent weakness a buying opportunity, says Summit Research
Subscribe for More Information
05:57 EDTARMHUMC collaborates with ARM to validate UMC 14nm FinFET process
Subscribe for More Information
05:45 EDTFEYEFireEye downgraded to Neutral from Buy at UBS
UBS analyst Brent Thill downgraded FireEye (FEYE) to Neutral citing the stock's 70% rally year-to-date. Hill, however, raised his price target for name to $55 from $50. Shares of the cybersecurity provider closed Friday down 58c to $53.65. Hill also downgraded Symantec (SYMC) this morning to Sell. In the cybersecurity space, he keeps Buy ratings on Palo Alto Networks (PANW) and Fortinet (FTNT).
June 21, 2015
15:42 EDTCACICACI to hold a conference call
Management holds a conference call to discuss fiscal year 2016 annual guidance on June 25 at 8:30 am. Webcast Link
June 19, 2015
14:50 EDTNKENike June weekly volatility elevated into Q4 and growth outlook
Subscribe for More Information
10:34 EDTLLYEli Lilly to host conference call
Subscribe for More Information
08:22 EDTVIPSChina to let foreign companies fully own e-commerce businesses, Reuters reports
China's Ministry of Industry and Information Technology announced that, effective immediately, foreign companies will be allowed to have full ownership of some e-commerce businesses, reported Reuters. Players in China's booming e-commerce market include market leader Alibaba Group (BABA) as well as JD.com (JD), Amazon.com (AMZN), Vipshop (VIPS) Wal-Mart (WMT), which holds a stake in shopping site Yihaodian, the report noted. Reference Link
08:04 EDTLLYEli Lilly publishes results of Phase III REACH trial evaluating Cyramza
Subscribe for More Information
07:23 EDTLLYTeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.
June 18, 2015
17:03 EDTNKENike boardmembers Douglas G. Houser and Orin C. Smith retiring in September
Subscribe for More Information
06:57 EDTMNKMallinckrodt says Questcor facing multi-state antitrust probe
Subscribe for More Information
05:33 EDTALGTAllegiant Travel upgraded to Equal Weight from Underweight at Barclays
Barclays upgraded Allegiant Travel to Equal Weight citing easing labor risks. The firm raised its price target for shares to $200 from $167.
June 17, 2015
12:02 EDTLLYEli Lilly reports LY2951742 meets primary endpoint in Phase 2b migraine study
Eli Lilly announced that its investigational medicine for prevention of migraine -- LY2951742, a CGRP neutralizing antibody -- met the primary endpoint in a Phase 2b study in episodic migraine. The randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of four different doses of LY2951742 given in a once-monthly, subcutaneous injection in more than 400 patients with episodic migraine. The primary objective was to assess whether at least one dose of LY2951742 was superior to placebo in the prevention of migraine headache. LY2951742 demonstrated a statistically significant reduction in migraine headache days and a safety and tolerability profile confirming the previous results seen in a Phase 2a study. In addition to the migraine program, Lilly has initiated two Phase 3 trials with LY2951742 in patients suffering from cluster headache. Based on the unmet medical need and significance of this disorder for patients, Lilly has been granted fast track designation from the U.S. FDA for cluster headache.
11:47 EDTFEYECyberArk rises after Merrill hikes target noting strong security trends
Subscribe for More Information
10:00 EDTLLYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
08:10 EDTLLYEli Lilly and Dana-Farber Cancer Institute enter research collaboration
Subscribe for More Information
08:02 EDTLLYEli Lilly partnering with Sarah Cannon Research Institute for oncology therapy
Eli Lilly and Sarah Cannon Research Institute announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
07:25 EDTLLYPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
07:21 EDTMNKGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
05:31 EDTLLYEli Lilly initiated with an Overweight at Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use